Clinical implications. In vitro resistance of E coli to TMP/SMX.
出版信息
Postgrad Med. 2001 Aug;110(2 Suppl):11-5; discussion 26-7. doi: 10.3810/pgm.08.2001.suppl15.82.
Abstract
摘要
相似文献
1
Clinical implications. In vitro resistance of E coli to TMP/SMX.
Postgrad Med. 2001 Aug;110(2 Suppl):11-5; discussion 26-7. doi: 10.3810/pgm.08.2001.suppl15.82.
2
In vitro resistance of E coli to TMP/SMX and clinical failure.
Postgrad Med. 2001 Aug;110(2 Suppl):9-10; discussion 26-7. doi: 10.3810/pgm.08.2001.suppl15.81.
3
Increasing in vitro resistance of E coli to TMP/SMX.
Postgrad Med. 2001 Aug;110(2 Suppl):5-8; discussion 26-7. doi: 10.3810/pgm.08.2001.suppl15.80.
4
The role of clinical guidelines.
Postgrad Med. 2001 Aug;110(2 Suppl):16-20; discussion 26-7. doi: 10.3810/pgm.08.2001.suppl15.83.
5
Susceptibility of antimicrobial-resistant urinary Escherichia coli isolates to fluoroquinolones and nitrofurantoin.
Clin Infect Dis. 2003 Jan 15;36(2):183-7. doi: 10.1086/345754. Epub 2003 Jan 3.
6
Prevalence and predictors of trimethoprim-sulfamethoxazole resistance among uropathogenic Escherichia coli isolates in Michigan.
Clin Infect Dis. 2002 Apr 15;34(8):1061-6. doi: 10.1086/339491. Epub 2002 Mar 11.
7
Empirical therapy for uncomplicated urinary tract infections in an era of increasing antimicrobial resistance: a decision and cost analysis.
Clin Infect Dis. 2001 Sep 1;33(5):615-21. doi: 10.1086/322603. Epub 2001 Jul 30.
8
Trimethoprim/sulfamethoxazole resistance in urinary tract infections.
J Emerg Med. 2009 May;36(4):338-41. doi: 10.1016/j.jemermed.2007.08.068. Epub 2008 Mar 6.
9
Urinary tract infection.
N Engl J Med. 2003 Oct 23;349(17):1674-6; author reply 1674-6. doi: 10.1056/NEJM200310233491720.
10
Escherichia coli resistance in uncomplicated urinary tract infection: a model for determining when to change first-line empirical antibiotic choice.
Manag Care Interface. 2002 Jun;15(6):35-42.
Zotero 插件